In September of 2019, just months before Covid hysteria made its way through the world, The Gates Foundation secured its shares in the Pfizer vaccine partner through a pre-IPO equity deal with anagreed upon purchase price of $18.10 per share. With an average sale price of around $300 per share in Q3 of 2021, this means that the Gates Foundation banked roughly $260 million in cash from the sale, with $242 million being untaxed profit, given that the money was invested through the foundation. And that doesn’t account for the additional 2 million shares that the Gates Foundation sold prior to that from its original pre-IPO equity investment. In the Q3 2021 sale, the Gates Foundation secured a return of over 15 times more than its initial investment.

link